Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis

Alexandre S. Basso, Dan Frenkel, Francisco J. Quintana, Frederico A. Costa-Pinto, Sanja Petrovic-Stojkovic, Lindsay Puckett, Alon Monsonego, Amnon Bar-Shir, Yoni Engel, Michael Gozin, Howard L. Weiner

Research output: Contribution to journalArticle

Abstract

Axonal degeneration is an important determinant of progressive neurological disability in multiple sclerosis (MS). Thus, therapeutic approaches promoting neuroprotection could aid the treatment of progressive MS. Here, we used what we believe is a novel water-soluble fullerene derivative (ABS-75) attached to an NMDA receptor antagonist, which combines antioxidant and anti-excitotoxic properties, to block axonal damage and reduce disease progression in a chronic progressive EAE model. Fullerene ABS-75 treatment initiated after disease onset reduced the clinical progression of chronic EAE in NOD mice immunized with myelin-oligodendrocyte glycoprotein (MOG). Reduced disease progression in ABS-75-treated mice was associated with reduced axonal loss and demyelination in the spinal cord. Fullerene ABS-75 halted oxidative injury, CD11b+ infiltration, and CCL2 expression in the spinal cord of mice without interfering with antigen-specific T cell responses. In vitro, fullerene ABS-75 protected neurons from oxidative and glutamate-induced injury and restored glutamine synthetase and glutamate transporter expression in astrocytes under inflammatory insult. Glutamine synthetase expression was also increased in the white matter of fullerene ABS-75-treated animals. Our data demonstrate the neuroprotective effect of treatment with a fullerene compound combined with a NMDA receptor antagonist, which may be useful in the treatment of progressive MS and other neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)1532-1543
Number of pages12
JournalJournal of Clinical Investigation
Volume118
Issue number4
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Fullerenes
Multiple Sclerosis
Glutamate-Ammonia Ligase
N-Methyl-D-Aspartate Receptors
Disease Progression
Spinal Cord
Myelin-Oligodendrocyte Glycoprotein
Amino Acid Transport System X-AG
Inbred NOD Mouse
Wounds and Injuries
Demyelinating Diseases
Neuroprotective Agents
Astrocytes
Neurodegenerative Diseases
Glutamic Acid
Antioxidants
T-Lymphocytes
Neurons
Antigens
Water

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Basso, A. S., Frenkel, D., Quintana, F. J., Costa-Pinto, F. A., Petrovic-Stojkovic, S., Puckett, L., ... Weiner, H. L. (2008). Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. Journal of Clinical Investigation, 118(4), 1532-1543. https://doi.org/10.1172/JCI33464

Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. / Basso, Alexandre S.; Frenkel, Dan; Quintana, Francisco J.; Costa-Pinto, Frederico A.; Petrovic-Stojkovic, Sanja; Puckett, Lindsay; Monsonego, Alon; Bar-Shir, Amnon; Engel, Yoni; Gozin, Michael; Weiner, Howard L.

In: Journal of Clinical Investigation, Vol. 118, No. 4, 01.04.2008, p. 1532-1543.

Research output: Contribution to journalArticle

Basso, AS, Frenkel, D, Quintana, FJ, Costa-Pinto, FA, Petrovic-Stojkovic, S, Puckett, L, Monsonego, A, Bar-Shir, A, Engel, Y, Gozin, M & Weiner, HL 2008, 'Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis', Journal of Clinical Investigation, vol. 118, no. 4, pp. 1532-1543. https://doi.org/10.1172/JCI33464
Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. Journal of Clinical Investigation. 2008 Apr 1;118(4):1532-1543. https://doi.org/10.1172/JCI33464
Basso, Alexandre S. ; Frenkel, Dan ; Quintana, Francisco J. ; Costa-Pinto, Frederico A. ; Petrovic-Stojkovic, Sanja ; Puckett, Lindsay ; Monsonego, Alon ; Bar-Shir, Amnon ; Engel, Yoni ; Gozin, Michael ; Weiner, Howard L. / Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. In: Journal of Clinical Investigation. 2008 ; Vol. 118, No. 4. pp. 1532-1543.
@article{294a351bc13f4c299a79fe7e71f39b89,
title = "Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis",
abstract = "Axonal degeneration is an important determinant of progressive neurological disability in multiple sclerosis (MS). Thus, therapeutic approaches promoting neuroprotection could aid the treatment of progressive MS. Here, we used what we believe is a novel water-soluble fullerene derivative (ABS-75) attached to an NMDA receptor antagonist, which combines antioxidant and anti-excitotoxic properties, to block axonal damage and reduce disease progression in a chronic progressive EAE model. Fullerene ABS-75 treatment initiated after disease onset reduced the clinical progression of chronic EAE in NOD mice immunized with myelin-oligodendrocyte glycoprotein (MOG). Reduced disease progression in ABS-75-treated mice was associated with reduced axonal loss and demyelination in the spinal cord. Fullerene ABS-75 halted oxidative injury, CD11b+ infiltration, and CCL2 expression in the spinal cord of mice without interfering with antigen-specific T cell responses. In vitro, fullerene ABS-75 protected neurons from oxidative and glutamate-induced injury and restored glutamine synthetase and glutamate transporter expression in astrocytes under inflammatory insult. Glutamine synthetase expression was also increased in the white matter of fullerene ABS-75-treated animals. Our data demonstrate the neuroprotective effect of treatment with a fullerene compound combined with a NMDA receptor antagonist, which may be useful in the treatment of progressive MS and other neurodegenerative diseases.",
author = "Basso, {Alexandre S.} and Dan Frenkel and Quintana, {Francisco J.} and Costa-Pinto, {Frederico A.} and Sanja Petrovic-Stojkovic and Lindsay Puckett and Alon Monsonego and Amnon Bar-Shir and Yoni Engel and Michael Gozin and Weiner, {Howard L.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1172/JCI33464",
language = "English (US)",
volume = "118",
pages = "1532--1543",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis

AU - Basso, Alexandre S.

AU - Frenkel, Dan

AU - Quintana, Francisco J.

AU - Costa-Pinto, Frederico A.

AU - Petrovic-Stojkovic, Sanja

AU - Puckett, Lindsay

AU - Monsonego, Alon

AU - Bar-Shir, Amnon

AU - Engel, Yoni

AU - Gozin, Michael

AU - Weiner, Howard L.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Axonal degeneration is an important determinant of progressive neurological disability in multiple sclerosis (MS). Thus, therapeutic approaches promoting neuroprotection could aid the treatment of progressive MS. Here, we used what we believe is a novel water-soluble fullerene derivative (ABS-75) attached to an NMDA receptor antagonist, which combines antioxidant and anti-excitotoxic properties, to block axonal damage and reduce disease progression in a chronic progressive EAE model. Fullerene ABS-75 treatment initiated after disease onset reduced the clinical progression of chronic EAE in NOD mice immunized with myelin-oligodendrocyte glycoprotein (MOG). Reduced disease progression in ABS-75-treated mice was associated with reduced axonal loss and demyelination in the spinal cord. Fullerene ABS-75 halted oxidative injury, CD11b+ infiltration, and CCL2 expression in the spinal cord of mice without interfering with antigen-specific T cell responses. In vitro, fullerene ABS-75 protected neurons from oxidative and glutamate-induced injury and restored glutamine synthetase and glutamate transporter expression in astrocytes under inflammatory insult. Glutamine synthetase expression was also increased in the white matter of fullerene ABS-75-treated animals. Our data demonstrate the neuroprotective effect of treatment with a fullerene compound combined with a NMDA receptor antagonist, which may be useful in the treatment of progressive MS and other neurodegenerative diseases.

AB - Axonal degeneration is an important determinant of progressive neurological disability in multiple sclerosis (MS). Thus, therapeutic approaches promoting neuroprotection could aid the treatment of progressive MS. Here, we used what we believe is a novel water-soluble fullerene derivative (ABS-75) attached to an NMDA receptor antagonist, which combines antioxidant and anti-excitotoxic properties, to block axonal damage and reduce disease progression in a chronic progressive EAE model. Fullerene ABS-75 treatment initiated after disease onset reduced the clinical progression of chronic EAE in NOD mice immunized with myelin-oligodendrocyte glycoprotein (MOG). Reduced disease progression in ABS-75-treated mice was associated with reduced axonal loss and demyelination in the spinal cord. Fullerene ABS-75 halted oxidative injury, CD11b+ infiltration, and CCL2 expression in the spinal cord of mice without interfering with antigen-specific T cell responses. In vitro, fullerene ABS-75 protected neurons from oxidative and glutamate-induced injury and restored glutamine synthetase and glutamate transporter expression in astrocytes under inflammatory insult. Glutamine synthetase expression was also increased in the white matter of fullerene ABS-75-treated animals. Our data demonstrate the neuroprotective effect of treatment with a fullerene compound combined with a NMDA receptor antagonist, which may be useful in the treatment of progressive MS and other neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=41849124231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849124231&partnerID=8YFLogxK

U2 - 10.1172/JCI33464

DO - 10.1172/JCI33464

M3 - Article

C2 - 18340379

AN - SCOPUS:41849124231

VL - 118

SP - 1532

EP - 1543

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -